You have read all your free articles, to continue reading subscribe to read the rest of this content.
MedImmune, AstraZeneca's global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme. The trials are testing Imfinzi (dAlready a subscriber Login You have…
AstraZeneca and MSD have announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza(olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gAlready a subscriber Login You have read all…
BerGenBio has announced that dosing has commenced in the Phase II clinical trial assessing bemcentinib in hospitalized COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study, launcAlready a subscriber Login You have read all your free articles, to continue…
NeuroVive Pharmaceutical announces that an abstract with novel preclinical cancer data related to the company's sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summitto take place in Geneva, Switzerland, 2-5 February, 2017. In preclinical studAlready a subscriber Login You have read all your free articles,…
